Evidence map›Paper›PMID 36139987›Full record

ArticleAntibiotics (Basel, Switzerland)2022

Novel Megaplasmid Driving NDM-1-Mediated Carbapenem Resistance in

Mario Quezada-Aguiluz, Andrés Opazo-Capurro, Nilton Lincopan, Fernanda Esposito, Bruna Fuga, Sergio Mella-Montecino, Gisela Riedel, Celia A Lima, Helia Bello-Toledo, Marcela Cifuentes and 4 more

Abstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Clonal Dissemination of Pandrug-ResistantInternational journal of molecular sciences · 2025
    Article
  2. Genomic Diversity of NDM-ProducingAntibiotics (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mario Quezada-AguiluzLaboratorio de Investigación en Agentes Antibacterianos (LIAA-UdeC), Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción 4030000, Chile.ORCID 0000-0001-9644-8368
Andrés Opazo-CapurroLaboratorio de Investigación en Agentes Antibacterianos (LIAA-UdeC), Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción 4030000, Chile.ORCID 0000-0002-6382-7625
Nilton LincopanDepartment of Clinical Analysis, School of Pharmacy, University of São Paulo, São Paulo 05508-000, Brazil.ORCID 0000-0003-0161-5800
Fernanda EspositoDepartment of Clinical Analysis, School of Pharmacy, University of São Paulo, São Paulo 05508-000, Brazil.
Bruna FugaDepartment of Clinical Analysis, School of Pharmacy, University of São Paulo, São Paulo 05508-000, Brazil.
Sergio Mella-MontecinoDepartamento de Medicina Interna, Facultad de Medicina, Universidad de Concepción, Concepción 4030000, Chile.
Gisela RiedelDepartamento de Medicina Interna, Facultad de Medicina, Universidad de Concepción, Concepción 4030000, Chile.
Celia A LimaLaboratorio de Investigación en Agentes Antibacterianos (LIAA-UdeC), Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción 4030000, Chile.
Helia Bello-ToledoLaboratorio de Investigación en Agentes Antibacterianos (LIAA-UdeC), Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción 4030000, Chile.ORCID 0000-0002-9277-4681
Marcela CifuentesServicio de Laboratorio Clínico, Hospital Clínico Universidad de Chile, Santiago 8320000, Chile.
Francisco Silva-OjedaServicio de Laboratorio Clínico, Hospital Clínico Universidad de Chile, Santiago 8320000, Chile.
Boris BarreraServicio de Laboratorio Clínico, Hospital Clínico Universidad de Chile, Santiago 8320000, Chile.
Juan C HormazábalSubdepartamento de Enfermedades Infecciosas, Instituto de Salud Pública de Chile (ISP), Santiago 8320000, Chile.
Gerardo González-RochaLaboratorio de Investigación en Agentes Antibacterianos (LIAA-UdeC), Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción 4030000, Chile.ORCID 0000-0003-2351-1236

Funding

National Fund for Scientific and Technological Development, FONDECYT 11190602National Fund for Scientific and Technological Development, FONDECYT 1130838
6 · The paper itself

Abstract

Carbapenem-resistant Enterobacterales (CRE) is a critical public health problem in South America, where the prevalence of NDM metallo-betalactamases has increased substantially in recent years. In this study, we used whole genome sequencing to characterize a multidrug-resistant (MDR)

Indexed as

carbapenemasescarbapenem-resistant EnterobacteralesKlebsiella pneumoniaeNDM-1plasmid transfer

Identifiers

PMID36139987
PMCPMC9494972

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.